FMR LLC grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,908,918 shares of the company's stock after acquiring an additional 286,052 shares during the period. FMR LLC owned 0.09% of Takeda Pharmaceutical worth $41,365,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock valued at $43,000 after acquiring an additional 859 shares during the last quarter. Smithfield Trust Co grew its stake in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock worth $49,000 after buying an additional 1,490 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Takeda Pharmaceutical during the second quarter worth $59,000. Hexagon Capital Partners LLC lifted its holdings in shares of Takeda Pharmaceutical by 34.3% during the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company's stock worth $63,000 after purchasing an additional 1,129 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company's stock worth $76,000 after purchasing an additional 2,330 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.
Takeda Pharmaceutical Trading Down 0.5 %
TAK stock traded down $0.07 during midday trading on Friday, hitting $13.73. The stock had a trading volume of 960,400 shares, compared to its average volume of 1,799,622. The firm has a market cap of $43.69 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The business has a fifty day moving average price of $13.88 and a two-hundred day moving average price of $13.86.
Takeda Pharmaceutical Company Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
